Baseline characteristics of patients in the study groups
Parameter | Group 1 | Group 2 | P |
---|---|---|---|
Number (patients/eyes) | 101/101 | 176/176 | N/A |
Age, years (mean ± SD) | 68.32 ± 9.49 | 70.44 ± 8.71 | 0.167 |
Male/female | 53/48 | 91/85 | 0.663 |
BCVA (mean ± SD) | 0.441 ± 0.392 | 0.510 ± 0.372 | 0.154 |
IOP (mean ± SD, mm Hg) | 24.99 ± 6.47 | 25.32 ± 4.88 | 0.659 |
The number of glaucoma medications (mean ± SD) | 3.139 ± 0.617 | 3.233 ± 0.593 | 0.215 |
P: statistical significance level; N/A: not applicable
SNS: Conceptualization, Methodology, Investigation, Data curation, Formal Analysis, Writing—original draft, Writing—review & editing. ANA: Conceptualization, Investigation, Writing—review & editing. AVS and SVS: Investigation, Writing—review & editing. ANS: Visualization, Writing—review & editing. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
This study is approved by the Institutional Ethics Committee of Volga District Medical Center under the Federal Medical and Biological Agency No. 7 of 31 May 2022 and complies with the Declaration of Helsinki.
Informed consent to participate in the study was obtained from all participants.
Not applicable.
The primary data will not be shared with third parties due to the institution’s policy regarding patient data.
Not applicable.
© The Author(s) 2023.